{"schema_version":"secwatch.filing_event.v1","accession":"0001001233-25-000006","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.102378+00:00","generated_at":"2026-05-17T08:11:32.826371+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026","bullets":["Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.","All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.","69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.","BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.","Company notes need for substantial additional capital to continue as going concern and advance Fabry program."],"urls":{"canonical":"https://secwatch.observer/filing/0001001233-25-000006","json":"https://secwatch.observer/filing/0001001233-25-000006.json","markdown":"https://secwatch.observer/filing/0001001233-25-000006.md","text":"https://secwatch.observer/filing/0001001233-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/0001001233-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/sgmo-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:11:32.826371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}